Logo Logo Logo Logo Logo
  • Home
  • About
    • About Atomo
    • Board of Directors
    • Executive Team
    • Governance
  • OEM Devices
    • Device Platforms
      • Elion RDT platform
      • Pascal RDT platform
      • Galileo RDT platform
      • Losev RDT platform
      • Newton RDT platform
      • Franklin RDT platform
    • OEM Service
      • Development Pathway
  • COVID-19
  • HIV
    • HIV Professional Use Test
    • HIV Self Testing
  • News
    • News
  • Investor Centre
  • Contact
    • Media Centre
  • Home
  • About
    • About Atomo
    • Board of Directors
    • Executive Team
    • Governance
  • OEM Devices
    • Device Platforms
      • Elion RDT platform
      • Pascal RDT platform
      • Galileo RDT platform
      • Losev RDT platform
      • Newton RDT platform
      • Franklin RDT platform
    • OEM Service
      • Development Pathway
  • COVID-19
  • HIV
    • HIV Professional Use Test
    • HIV Self Testing
  • News
    • News
  • Investor Centre
  • Contact
    • Media Centre

10 Sep Interview with Proactive Investors

Posted at 20:54h in News by Rebecca James 0 Comments
0 Likes

Managing Director, John Kelly speaks to Proactive about the broad applications for Atomo’s rapid blood-based tests at the ASX Small and Mid-Cap Conference.

 

Tags:
ASX, Atomo Diagnostics, Lateral Flow, Rapid Diagnostic Test
Copyright 2020 Atomo Diagnostics
Privacy Policy
Australia (Head Office) Level 2, 701-703 Parramatta Road, Leichhardt, NSW 2040 Telephone: +61 (0)2 9099 4750